抄録
Recent advances in genomics and molecular technologies have given a potential to revolutionize cancer therapy. Most of the existing chemotherapeutic treatments are palliative in the advanced solid tumors, and further responses to the therapies significantly vary among the patients. Genomic data and genome-wide analysis of gene expression derived from high throughput DNA sequencing and DNA chip have shown great promise for hunting novel drug targets in the broadest range and selecting optimal cancer therapy for individual patients through better diagnosis of an "at risk" subgroup. However, these challenges have not been always successful. To determine the critical genes from the large number of candidates, a tremendously large amount of data is statistically required. The methodology or the experimental design to exploit the full power of a global perspective is still controversial. Recent challenges for drug discovery and development of personalized medicine, including ours, are briefly reviewed.
